Novo Nordisk (NVO) closed at $38.17 in the latest trading session, marking a -3.12% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.76%. Meanwhile, the Dow lost 0.68%, and the Nasdaq, a tech-heavy index, lost 1.13%. The drugmaker's stock has dropped by 19.03% in the past month, falling short of the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%. Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.79, marking a 22.55% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.